Literature DB >> 22560821

Coeliac disease in irritable bowel syndrome (Rome III) in Southeast Iran.

Alireza Bakhshipour1, Seyyed Kazem Nezam, Zahra Zakeri, Reza Gharibi, Ali Bahari, Mahmoud Ali Kaykhaei.   

Abstract

BACKGROUND AND STUDY AIMS: Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder and coeliac disease (CD) is an auto-immune enteropathy that can mimic almost any functional GI disorder. Both IBS and coeliac disease share common symptoms. The aim of the present study was to estimate the prevalence of CD in patients with IBS and its sub-types. PATIENTS AND METHODS: In this cross-sectional study (2008-2010), all consecutive patients with IBS who fulfilled the Rome III criteria attending the GI units in Zahedan (Southeast Iran) were included. Patients based on the sub-type of IBS were classified as diarrhoea-predominant irritable bowel syndrome (D-IBS), constipation-predominant irritable bowel syndrome (C-IBS) and alternating symptoms (mixed type). Immunoglobulin A (IgA) tissue transglutaminase (anti-tTG) was used to screen patients for CD. In the case of positive serologic test, duodenal biopsies were taken to confirm the diagnosis.
RESULTS: A total of 364 (221 females and 143 males) patients with IBS were included. The mean ± standard deviation (SD) age of patients was 37.4 ± 12.4 years. Twenty (5.5%) patients were found to have positive IgA anti-tTG. Main symptoms of patients were diarrhoea (11/20), bloating (10/20) and abdominal distension (6/20). Thirteen (10.5%) patients were found to have positive IgA anti-tTG among the D-IBS, two (1.6%) in the C-IBS and five (4.2%) in M-IBS groups.
CONCLUSION: The prevalence of CD in IBS is high. IBS subjects whose main complaint is diarrhoea, bloating or even abdominal distension should be evaluated for CD.
Copyright © 2012 Arab Journal of Gastroenterology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22560821     DOI: 10.1016/j.ajg.2012.03.003

Source DB:  PubMed          Journal:  Arab J Gastroenterol        ISSN: 1687-1979            Impact factor:   2.076


  7 in total

1.  Comparison of fluoxetine and duloxetine hydrochloride therapeutic effects on patients with constipation-predominant irritable bowel syndrome.

Authors:  Sattar Jafari; Behnam Sajedi; Maryam Jameshorani; Fatemeh Salarpour
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

Review 2.  Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis.

Authors:  Andrew J Irvine; William D Chey; Alexander C Ford
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

3.  Prevalence of serum celiac antibodies in a multiracial Asian population--a first study in the young Asian adult population of Malaysia.

Authors:  Theresa Wan-Chen Yap; Weng-Kai Chan; Alex Hwong-Ruey Leow; Ahmad Najib Azmi; Mun-Fai Loke; Jamuna Vadivelu; Khean-Lee Goh
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

4.  Antigliadin antibody in sporadic adult ataxia.

Authors:  Yaser Hamidian; Mansoureh Togha; Shahriar Nafisi; Shahab Dowlatshahi; Soodeh Razeghi Jahromi; Nahid Beladi Moghadam; Navid Namazi; Parvin Tajik; Masoud Majed; Mahdi Aloosh
Journal:  Iran J Neurol       Date:  2012

5.  The prevalence of celiac disease in patients with irritable bowel syndrome and its subtypes.

Authors:  Danuta Domżał-Magrowska; Marek K Kowalski; Piotr Szcześniak; Magdalena Bulska; Daria Orszulak-Michalak; Ewa Małecka-Panas
Journal:  Prz Gastroenterol       Date:  2016-02-16

6.  Celiac disease in Iran: a systematic review and meta-analysis.

Authors:  Roghayeh Mohammadibakhsh; Rahim Sohrabi; Morteza Salemi; Masood Taheri Mirghaed; Masoud Behzadifar
Journal:  Electron Physician       Date:  2017-03-25

Review 7.  Celiac disease in Iranian irritable bowel syndrome patients; a systematic review and meta-analysis.

Authors:  Milad Azami; Gholamreza Badfar; Ghobad Abangah; Leily Mahmoudi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.